Technical Analysis for OSL - Oncosil Medical Ltd  

Grade Last Price % Change Price Change
F 0.007 0.00% 0.000
OSL closed unchanged on Thursday, November 21, 2024, on 36 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 28
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%

   Recent Intraday Alerts

Alert Time
Possible NR7 1 day ago
Gap Up Closed 2 days ago
Reversed from Up 2 days ago
10 DMA Resistance 2 days ago
1.5x Volume Pace 2 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Oncosil Medical Ltd   Description

OncoSil Medical Limited is a late-stage medical device company, which is focused on localized treatments for patients with pancreatic and liver cancer. The Company is engaged in the development of its lead product candidate, the OncoSil localized radiation therapy, for the treatment of pancreatic cancer. The Company's lead product, OncoSil, is a brachytherapy device that emits beta radiation and is implanted directly inside the cancerous tumor. OncoSil is a silicon and phosphorus (p32) beta emitter, able to be implanted intra-tumorally via endoscopic ultrasonography in localized solid tumors of patients with pancreatic cancer. The Company focuses on an application for Conformite Europeene (CE) Mark to enable commercial sales of OncoSil in the European Union and an application for an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA) to enable commencement of the United States pivotal clinical study, known as OncoPac-1.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Health Medicine Food Cement Cancer Medical Device Implant Therapy Medical Physics Tumor Radiation Tumors Radiation Therapy Solid Tumors European Union Pancreatic Cancer Phosphorus Pivot Radioactivity

Is OSL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.015
52 Week Low 0.004
Average Volume 8,436,645
200-Day Moving Average 0.008
50-Day Moving Average 0.011
20-Day Moving Average 0.008
10-Day Moving Average 0.008
Average True Range 0.001
RSI (14) 50.00
ADX 26.24
+DI 16.552
-DI 24.828
Chandelier Exit (Long, 3 ATRs) 0.009
Chandelier Exit (Short, 3 ATRs) 0.011
Upper Bollinger Bands 0.011
Lower Bollinger Band 0.005
Percent B (%b) 0.28
BandWidth 72.289
MACD Line -0.001
MACD Signal Line -0.001
MACD Histogram 0.0
Fundamentals Value
Market Cap 5.88 Million
Num Shares 839 Million
EPS -0.01
Price-to-Earnings (P/E) Ratio -0.50
Price-to-Sales 0.00
Price-to-Book 6.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.007
Resistance 3 (R3) 0.007 0.007 0.007
Resistance 2 (R2) 0.007 0.007 0.007 0.007
Resistance 1 (R1) 0.007 0.007 0.007 0.007 0.007
Pivot Point 0.007 0.007 0.007 0.007 0.007
Support 1 (S1) 0.007 0.007 0.007 0.007 0.007
Support 2 (S2) 0.007 0.007 0.007 0.007
Support 3 (S3) 0.007 0.007 0.007
Support 4 (S4) 0.007